Breaking News Instant updates and real-time market news.

FL

Foot Locker

, UA

Under Armour; also tag UAA

09:16
12/15/17
12/15
09:16
12/15/17
09:16

On The Fly: Pre-market Movers

HIGHER: Foot Locker (FL), up 2.7% after being upgraded to Buy from Hold at Canaccord... Under Armour (UA, UAA), up 4.2% and 3.3%, respectively after being upgraded to Buy from Hold at Stifel... Polarityte (COOL), up 5.3% after announcing the application of SkinTE on first patients... Aclaris Therapeutics (ACRS), up 1.9% after receiving FDA approval for Eskata topical solution, 40%. LOWER: CSX (CSX), down 10.8% after announcing that CEO E. Hunter Harrison is on medical leave due to unexpected complications from a recent illness... Radius Health (RDUS), down 4.1% after announcing the Committee for Medicinal Products for Human Use will issue a third Day-180 List of Outstanding Issues. As part of its on-going risk-benefit assessment, the CHMP has informed the company that it intends to refer the marketing authorisation application, or MAA, to a scientific advisory group for additional advice.

FL

Foot Locker

UA

Under Armour; also tag UAA

UAA

Under Armour; also tag UA

COOL

PolarityTE

$24.19

-1.95 (-7.46%)

ACRS

Aclaris Therapeutics

$24.72

-0.38 (-1.51%)

CSX

CSX

$57.31

-0.38 (-0.66%)

RDUS

Radius Health

$28.66

-0.96 (-3.24%)

  • 24

    Dec

FL Foot Locker

12/04/17
12/04/17
DOWNGRADE

Hold
Foot Locker downgraded to Hold with 'rare loss' at Standpoint Research
As previously reported, Standpoint Research analyst Ronnie Moas downgraded Foot Locker to Hold from Buy, saying it "is very rare for me to close a position out at a loss" but following the 60% bounce from the stock's low he is doing that in this case. Moas now wonders if Foot Locker is a value trap given declining shopping mall numbers and foot traffic in the U.S.
12/15/17
ADAM
12/15/17
UPGRADE
ADAM
Buy
Foot Locker upgraded to Buy from Hold at Canaccord
12/04/17
STPT
12/04/17
DOWNGRADE
STPT
Hold
Foot Locker downgraded to Hold from Buy at Standpoint Research
12/15/17
12/15/17
UPGRADE
Target $64

Buy
Foot Locker upgraded to Buy on end of inventory clearance at Canaccord
As previously reported, Canaccord analyst Camilo Lyon upgraded Foot Locker (FL) to Buy from Hold, stating that he believes the company is approaching the end of the inventory clearance cycle it has been in for the past three quarters. His recent travels with management made it clear that the company's relationship with Nike (NKE) is "strong and symbiotic" and that recent comp declines are due to cyclical factors, not structural ones, he added. Lyon raised his price target on Foot Locker shares to $64 from $42.
UA Under Armour; also tag UAA

11/22/17
STFL
11/22/17
NO CHANGE
Target $12
STFL
Hold
Under Armour continued executive turnover 'troubling,' says Stifel
After The Wall Street Journal reported that Peter Ruppe, SVP of Footwear, will be leaving Under Armour, Stifel analyst Jim Duffy noted that this follows a number of other senior executive departures in the past twelve months, which he sees suggesting "troubling" instability and lack of clear direction. However, the recent addition of Patrik Frisk as President and COO holds promise to introduce leadership continuity, said Duffy, who keeps a Hold rating and $12 price target on Under Armour shares.
12/15/17
STFL
12/15/17
UPGRADE
Target $17
STFL
Buy
Under Armour upgraded to Buy from Hold at Stifel
Stifel analyst Jim Duffy upgraded Under Armour to Buy from Hold, saying he expects the company's business to be in a much better position entering 2019 and for the stock to begin to anticipate improvements before it shows in reported results. Duffy, who is looking for a return to full-price apparel and footwear sales at retail and signs of margin improvement, raised his price target on Under Armour shares to $17 from $12.
12/14/17
DBAB
12/14/17
UPGRADE
Target $11
DBAB
Hold
Finish Line upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Paul Trussell upgraded Finish Line (FINL) to Hold and raised his price target for the shares to $11 from $5. The analyst sees sector headwinds alleviating in fiscal 2018 as Nike (NKE) delivers product newness and overall inventory levels scale back, leading to a less promotional environment. He believes Finish Line's efforts to improve assortment, store experience and vendor relationships will lead to a modestly better sales results. Trussell also raised his price target for Nike shares to $76 from $61 and for Under Armour (UAA) to $12 from $11.
11/15/17
BARD
11/15/17
NO CHANGE
Target $17
BARD
Outperform
Under Armour showing signs of better demand and execution, says Baird
Baird analyst Jonathan Komp said there are signs for Under Armour of better reception for the Curry 4 basketball shoe and better execution too. He believes it may still be early but the rebound in the Curry shoe, continued international strength, and broadening distribution could provide ingredients for a return to healthier footwear growth in the upcoming quarters. Komp maintained his Outperform rating and $17 price target on Under Armour shares.
UAA Under Armour; also tag UA

COOL PolarityTE
$24.19

-1.95 (-7.46%)

ACRS Aclaris Therapeutics
$24.72

-0.38 (-1.51%)

09/19/17
CANT
09/19/17
NO CHANGE
Target $50
CANT
Overweight
Public FDA meeting positive for Aclaris, says Cantor
The FDA last Monday conducted a public meeting on alopecia areata patient-focused drug development, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. The meeting was constructive on alopecia as a disease and the need to get drugs approved, the analyst contends. She believes the meeting is a positive for Aclaris Therapeutics, which she notes is working on "several solutions to the problem." Chen has an Overweight rating on Aclaris with a $50 price target.
06/16/17
CANT
06/16/17
INITIATION
Target $50
CANT
Overweight
Aclaris Therapeutics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Aclaris Therapeutics with an Overweight rating and $50 price target.
04/26/17
LEER
04/26/17
NO CHANGE
Target $54
LEER
Outperform
Aclaris patent could be worth $15 per share, says Leerink
Leerink analyst Seamus Fernandez believes the A-101 patent announced today by Aclaris Therapeutics could add $15 per share to the company's net present value. The newly allowed patent expires in 2035, 11 years later than the analyst currently assumes loss of exclusivity in seborrheic keratosis. Extending the patent life of A-101 could increase the NPV contribution to $31 per share from $16, Fernandez tells investors in a research note. He keeps an Outperform rating on Aclaris with a $54 price target.
CSX CSX
$57.31

-0.38 (-0.66%)

12/01/17
UBSW
12/01/17
NO CHANGE
Target $68
UBSW
Buy
CSX upside remains compelling, says UBS
UBS analyst Thomas Wadewitz met with CSX management and said the new COO brings a thoughtful approach and fresh perspective on the business. The analyst believes the company is set up to deliver a significant improvement in its network operation and compelling cost reduction in 2018. He said capital expenditures will decrease and its stock buyback remains underappreciated. Wadewitz reiterated his Buy rating and $68 price target on CSX shares.
11/17/17
UBSW
11/17/17
NO CHANGE
Target $68
UBSW
Buy
CSX shares attractive, reflecting too much caution, says UBS
UBS analyst Thomas Wadewitz said CSX is in transition and is expected to be focused on improving operational execution with rising momentum in the first half of 2018 while switching to focusing on volumes and growth a longer term priority. The analyst said that given the company's potential the shares are reflecting too much caution. He reiterated his Buy rating and $68 price target on CSX shares.
11/13/17
GSCO
11/13/17
INITIATION
Target $45
GSCO
Sell
CSX initiated with a Sell at Goldman Sachs
Goldman Sachs analyst Matt Reustle started CSX with a Sell rating and $45 price target. The analyst started the Rails sector with a Cautious coverage view and the Airfreight/Logistics sector with an Attractive coverage view. Reustle believes investors are "overestimating the speed and magnitude" of the earnings benefits from CSX's turnaround. He sees headwinds to the company's margin initiatives and notes the stock has outperformed since initial press speculation of the appointment of Hunter Harrison as CEO.
12/15/17
SBSH
12/15/17
NO CHANGE
Target $58
SBSH
Buy
CSX CEO leave to bring 'material' stock pressure, says Citi
Citi analyst Christian Wetherbee expects shares of CSX to be under "meaningful pressure" in the short term following last night's announcement that CEO Hunter Harrison will be taking a medical leave due to unexpected complications from a recent illness. The news triggers the "substantial key man risk" that has been present since Hunter took the reins in January, Wetherbee tells investors in a research note. He notes CSX's market capitalization has increased $10B since Harrison joined the company. The analyst keeps a Buy rating on the shares with a $58 price target, however. He believes Jim Foote's arrival "should cushion the blow somewhat."
RDUS Radius Health
$28.66

-0.96 (-3.24%)

05/22/17
JPMS
05/22/17
NO CHANGE
Target $74
JPMS
Overweight
Amgen data a 'clear positive' for Radius Health, says JPMorgan
JPMorgan analyst Jessica Fye believes the imbalance in observed cardiovascular serious adverse events reported by Amgen (AMGN) and UCB over the weekend for Evenity is a "clear positive" for Radius Health (RDUS). The FDA will now add results from the Phase 3 ARCH study to the regulatory review, and as a result Amgen does not expect U.S. approval for Evenity in 2017, Fye tells investors in a research note. The update is a "clear positive" for Radius Health, who has Tymlos already approved with a clean clinical safety profile, the analyst contends. She continues to believe Tymlos is well positioned for a successful launch into the large market opportunity of postmenopausal women with osteoporosis at high risk of fracture. Fye has an Overweight rating on Radius with a $74 price target. The stock in premarket trading is up 13%, or $4.62, to $39.55.
05/22/17
LEER
05/22/17
NO CHANGE
Target $159
LEER
Market Perform
Leerink sees only 50/50 chance of Amgen's Evenity hitting market
After Amgen (AMGN) and UCB reported an "imbalance of positively adjudicated serious cardiovascular adverse events" in its Phase 3 study of Evenity, Leerink analyst Geoffrey Porges believes the product now has only a 50/50 probability of coming to market at all. The analyst lowered his price target for Amgen shares to $159 from $160 and keeps a Market Perform rating on the name. Radius Health (RDUS), which has a drug that would compete with Evenity, is trading up 16% to $40.58 in the premarket.
05/22/17
ADAM
05/22/17
NO CHANGE
Target $85
ADAM
Buy
CV events 'may kill' Amgen's romosozumab development, says Canaccord
Canaccord analyst John Newman said Amgen (AMGN) and partner UCB's report of a higher rate of cardiovascular Serious Adverse Events for romosozumab in the Phase 3 ARCH study in osteoporosis suggests a much lower chance of FDA approval for the drug and may "kill" romosozumab's development. He notes that Merck's (MRK) cathepsin-K inhibitor was previously discontinued due to increased risk of atrial fibrillation and stroke. In addition to the safety signals, Newman points out that romosozumab was worse than Radius' (RDUS) Tymlos for non-vertebral fracture and for vertebral fracture, suggesting Radius' drug also has much better efficacy, said the analyst, who keeps a Buy rating and $85 price target on Radius Health shares, which are up $4.47, or 12.8%, to $39.40 in pre-market trading.
12/06/17
SBSH
12/06/17
INITIATION
Target $30
SBSH
Neutral
Radius Health initiated with a Neutral at Citi
Citi analyst Robyn Karnauskas started Radius Health with a Neutral rating and $30 price target. The analyst believes the Tymlos launch will be the key story for 2018 and prefers to wait on the sidelines until the company's cancer program comes to the forefront.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.